Short-term efficacy of intravitreal dobesilate in central serous chorioretinopathy.
OBJECTIVE
To report the anatomic and functional outcome of intravitreal dobesilate to treat recurrent central serous chorioretinopathy (CSC).


METHODS
This is an interventional case report in which dobesilate was intravitreally injected in a case of recurrent CSC. Main measures included fundoscopy, Snellen visual acuity (VA) testing, fluorescein angiography and optical coherence tomography (OCT).


RESULTS
We present anatomical and functional evidences, obtained as early as eleven days after the treatment, of the efficacy of intravitreal dobesilate, in the treatment of chronic CSC condition. The effect after intravitreal dobesilate injection for CSC might be related to the normalization of retinal architecture.


CONCLUSIONS
Intravitreal dobesilate may be an effective treatment option for recurrent CSC.
Departamento de Investigación, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain. pedro.cuevas@hrc.es
Pedro
P
Cuevas
Luis A
LA
Outeiriño
Carlos
C
Azanza
Javier
J
Angulo
Guillermo
G
Giménez-Gallego
D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D000068258:Bevacizumab; D002123:Calcium Dobesilate / Q000008:administration & dosage / Q000627:therapeutic use*; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000473:pathology; D004979:Ethamsylate / Q000008:administration & dosage; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012160:Retina / Q000473:pathology; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome
D061067:Antibodies, Monoclonal, Humanized; D004979:Ethamsylate; D000068258:Bevacizumab; D002123:Calcium Dobesilate